Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)-Reference-Cited by-同舟云学术

Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)

Published:2021-01 Issue: Volume:151 Page:30-38
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Faivre-Finn Corinne,Spigel David R.,Senan Suresh,Langer Corey,Perez Bradford A.,Özgüroğlu Mustafa,Daniel Davey,Villegas Augusto,Vicente David,Hui Rina,Murakami Shuji,Paz-Ares Luis,Broadhurst Helen,Wadsworth Catherine,Dennis Phillip A.,Antonia Scott J.

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference37 articles.

1. Therapeutic management options for stage III non–small-cell lung cancer;Yoon;World J. Clin. Oncol.,2017

2. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer;Auperin;J. Clin. Oncol.,2010

3. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non–small-cell lung cancer: KCSG-LU05-04;Ahn;J. Clin. Oncol.,2015

4. Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non–small-cell lung cancer;Bradley;J. Clin. Oncol.,2020

5. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy;Biomarker Research;2024-09-04

2. Integrative Approaches in Non-Small Cell Lung Cancer Management: The Role of Radiotherapy;Journal of Clinical Medicine;2024-07-23

3. The future of cancer treatment: combining radiotherapy with immunotherapy;Frontiers in Molecular Biosciences;2024-07-09

4. Exploiting temporal aspects of cancer immunotherapy;Nature Reviews Cancer;2024-06-17

5. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R;ESMO Open;2024-06